Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 139,088 shares of the medical technology company’s stock after purchasing an additional 1,746 shares during the quarter. Rhumbline Advisers owned about 0.10% of Alphatec worth $1,277,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ATEC. R Squared Ltd acquired a new position in shares of Alphatec in the 4th quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 4,234 shares in the last quarter. Newton One Investments LLC acquired a new position in Alphatec in the fourth quarter worth approximately $50,000. XTX Topco Ltd acquired a new stake in shares of Alphatec during the third quarter worth $69,000. Finally, Van ECK Associates Corp lifted its position in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after acquiring an additional 6,998 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the sale, the chief executive officer now owns 5,501,715 shares in the company, valued at approximately $66,020,580. The trade was a 0.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 290,898 shares of company stock worth $3,327,710 over the last three months. Company insiders own 22.80% of the company’s stock.

Alphatec Stock Down 2.5 %

NASDAQ:ATEC opened at $11.44 on Thursday. The company has a market cap of $1.65 billion, a PE ratio of -8.94 and a beta of 1.43. The firm’s 50 day simple moving average is $10.81 and its 200 day simple moving average is $8.53. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $14.88.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. On average, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ATEC. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday, February 27th. Piper Sandler increased their price objective on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Barclays lifted their target price on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.